Abstract: 【Abstract】Objective to evaluate the role of paricalcitol in anti-inflammatory and anti-oxidative stress in maintenance hemodialysis (MHD) patients. Methods This study employed a pre- post self-comparison design method. A total of 23 MHD patients with secondary hyperparathyroidism (SHPT) treated in the Second Blood Purification Center, Shengjing Hospital, Chinese Medical University were enrolled in this study. After paricalcitol treatment for 2 months, the changes of biochemical, inflammatory and oxidative stress indices were evaluated in these patients. These indices included the biochemical indices of serum calcium after correction (cCa), phosphorus (P), intact parathyroid hormone (iPTH) and albumin (ALB); the inflammatory indices of peripheral white blood cells (WBC) and neutrophil cells (NE), serum C-reactive protein (CRP), interleukin-6 (IL-6), interleukin 8 (IL-8), interleukin 10 (IL-10) and tumor necrosis factor α (TNF-α); and the oxidative stress indices of serum malondialdehyde (MDA); superoxide dismutase (SOD), glutathione peroxidase (GSHPx), catalase (CAT) and thioredoxin (TRX). Based on the changes of biochemical indices examined monthly after the treatment, the dosage of paricalcitol was adjusted and the patients who did not meet the experimental requirements were excluded. A total of 21 patients finished the trial. SPSS 20.0 software was used to analyze the experimental results. Results After paricalcitol treatment for 2 months, the inflammatory indices decreased significantly, including CRP from (30.69 ± 6.03)mg/l to (22.12±8.89)mg/l (P=0.009), IL-6 from (10.44±4.52)pg/ml to (8.55±3.53)pg/ml (P=0.004), IL- 8 from (1637±315)pg/ml to (1338±221)pg/ml (P=0.002), TNF-α from (7.87±3.45)pg/ml to (6.22±2.41) pg/ml (P=0.018), but IL-10, WBC and NE had no statistical changes; oxidative stress indices increased significantly, including SOD from (875±323)U/g to (1572±454)U/g (P=0.001), TRX from (73.0 ± 24.6)ng/ml to 85.6 ± 30.9 ng/ml (P=0.025) and GSHPx from(75.10±12.96)U/mg to (84.29±20.24)U/mg (P=0.046), but MDA decreased from 9.31±1.93 nmol/ml to (7.79±2.44) nmol/ml (P=0.033), and CAT had no statistical change. Conclusion Paricalcitol can effectively treat SHPT, and at the same time, can improve the inflammatory
state and oxidative stress in MHD patients.

Key words: paricalcitol, maintenance hemodialysis, oxidative stress, inflammatory state, secondary hyperparathyroidism